Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 44.0 kDa. The protein migrates as 52-58 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Rhesus macaque CD4,His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Rhesus macaque CD4,His,Avitag (Cat. No. CD4-R82E3) is more than 90% and the molecular weight of this protein is around 43-53 kDa verified by SEC-MALS.
Immobilized Anti-CD4 Antibody (Ibalizumab-IgG4) at 1 μg/mL (100 μL/well) can bind Biotinylated Rhesus macaque CD4,His,Avitag (Cat. No. CD4-R82E3) with a linear range of 0.5-16 ng/mL (QC tested).
Immobilized Biotinylated Rhesus macaque CD4,His,Avitag (Cat. No. CD4-R82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD4 Antibody (Ibalizumab-IgG4) with a linear range of 0.1-2 ng/mL (Routinely tested).
Price(USD) : $350.00
Price(USD) : $1380.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ibalizumab | Hu5A8; TMB-355; TNX-355; 5AB | Approved | Biogen Inc | 特罗格佐, Trogarzo | EU | HIV Infections | Theratechnologies Europe Ltd | 2018-03-06 | HIV Infections | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CALRLong36 peptide (Herlev Hospital) | Phase 1 Clinical | Herlev Hospital | Myeloproliferative Disorders | Details | |
CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
TMB-365 | TMB-365 | Taimed Biologics Inc | Details | ||
SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Umoja BioPharma Inc | Details | ||
IMCY-0141 | IMCY-0141 | Imcyse Sa | Details | ||
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) | CAR-C34ZFN | University Of Pennsylvania | Details | ||
RB-0003 | RB-0003; BNT-111 | Biontech Se, Tron | Details | ||
Tregalizumab | hB-F5; BT-061 | Phase 2 Clinical | Biotest Pharma Gmbh | Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma | Details |
Mosedipimod | EC-18 | Phase 2 Clinical | Enzychem Lifesciences Co | Neutropenia; Coronavirus Disease 2019 (COVID-19); Stomatitis; Febrile Neutropenia | Details |
IT-1208 (Kyowa Hakko Kirin) | IT-1208 | Phase 1 Clinical | Kyowa Hakko Kirin Co Ltd | Neoplasms | Details |
GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
VRC-07-523 | VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral | Details |
VRC-01-LS | VRC-HIVMAB-080-00-AB; VRC-01-LS | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
10E8.4/iMab (Aaron Diamond AIDS Research Center) | TMB-370 | Phase 1 Clinical | Aaron Diamond Aids Research Center For The City Of New York, Inc | HIV Infections | Details |
T-allo-10 | T-allo-10 | Phase 1 Clinical | Stanford University | Hematologic Diseases; Graft vs Host Disease | Details |
CD4 CAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Lymphoma, T-Cell | Details | ||
CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) | CD4CAR (Icell Gene) | Phase 1 Clinical | Stony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of Louisville | Lymphoma, T-Cell; Leukemia, T-Cell | Details |
Autologous Regulatory Т-cell Therapy | Phase 2 Clinical | Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus | Scleroderma, Systemic | Details | |
VRC-HIVMAB091-00-AB | N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
LB-1901 | LB-1901; LB1901 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous | Details |
VRC-HIVMAB0115-00-AB | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
Semzuvolimab | dB4; UB-421; mAb-B4 | Phase 3 Clinical | United Biomedical Inc | HIV Infections | Details |
ITV 1(Nonindustrial source) | ITV-1 | Phase 3 Clinical | Synexa Life Sciences, Immunotech Laboratories, Nonindustrial Source | HIV Infections | Details |
This web search service is supported by Google Inc.